Purpose: To evaluate the effects of a mid-viscosity mucomimetic lubricant eye drop containing hydroxypropyl guar (HPG) as a gelling agent on computerized perimetry FASTPAC test results of primary open-angle glaucoma (POAG) patients with trachomatous dry eye. Methods: Both eyes of 33 patients with bilateral POAG and trachomatous dry eye were included in the study. They were treated with the same antiglaucomatous eye drop and underwent computerized perimetry. Before and after the treatment with lubricant eye drop (Systane™) for 8 weeks, tear function tests (Schirmer test with topical anesthesia, fluorescein staining and tear film break-up time) and FASTPAC test with computerized perimetry were performed. Pre- and posttreatment tear functions, visual field test global indices, reliability indices, test duration and numbers of depressed points in pattern deviation plots were compared. Results: We found significant improvements in tear function tests results, in computerized perimetry FASTPAC test indices, test duration and the number of depressed points in pattern deviation plots in the posttreatment evaluations. Conclusion: This study indicates that there was a benefit of mid-viscosity lubricant eye drop containing HPG treatment on computerized perimetry FASTPAC test performance in POAG subjects with trachomatous dry eye. We assume that the positive effect of this therapy is probably due to a better tear film stability, resulting in a higher optical quality of the repaired anterior corneal surface.

Keywords:
Primary open-angle glaucoma, Computerized perimetry, FASTPAC test strategy, Trachomatous dry eye, Lubricant eye drop, Hydroxypropyl guar
1.
Bron AJ: Diagnosis of dry eye. Surv Ophthalmol 2001;45:221–226.
2.
Behrens A, Doyle JJ, Stern L, Chuck RS, McDonnell PJ, Azar DT, Dua HS, Hom M, Karpecki PM, Laibson PR, Lemp MA, Meisler DM, Del Castillo JM, O’Brien TP, Pflugfelder SC, Rolando M, Schein OD, Seitz B, Tseng SC, van Setten G, Wilson SE, Yiu SC: Dysfunctional tear syndrome. A Delphi approach to treatment recommendation. Cornea 2006;25:900–907.
3.
Albarrán C, Pons AM, Lorente A, Montés R, Artigas JM: Influence of the tear film on optical quality of the eye. Cont Lens Anterior Eye 1997;20:129–135.
4.
Tutt R, Bradley A, Begley C, Thibos LN: Optical and visual impact of tear break-up in human eyes. Invest Ophthalmol Vis Sci 2000;41:4117–4123.
5.
Montés-Micó R, Alió JL, Muñoz G, Charman WN: Temporal changes in optical quality of air-tear film interface at anterior cornea after blink. Invest Ophthalmol Vis Sci 2004;45:1752–1757.
6.
Koh S, Maeda N, Kuroda T, Hori Y, Watanabe H, Fujikado T, Tano Y, Hirohara Y, Mihashi T: Effect of tear film break-up on higher-order aberrations measured with wavefront sensor. Am J Ophthalmol 2002;134:115–117.
7.
Montés-Micó R, Alió JL, Muñoz G, Pérez-Santonja JJ, Charman WN: Postblink changes in total and corneal ocular aberrations. Ophthalmology 2004;111:758–767.
8.
Koh S, Maeda N, Hirohara Y, Mihashi T, Ninomiya S, Bessho K, Watanabe H, Fujikado T, Tano Y: Serial measurements of higher-order aberrations after blinking in normal subjects. Invest Ophthalmol Vis Sci 2006;47:3318–3324.
9.
Goto E, Yagi Y, Matsumoto Y, Tsubota K: Impaired functional visual acuity of dry eye patients. Am J Ophthalmol 2002;133:181–186.
10.
Liu Z, Pflugfelder SC: Corneal surface regularity and the effect of artificial tears in aqueous tear deficiency. Ophthalmology 1999;106:939–943.
11.
Montés-Micó R, Cáliz A, Alió JL: Changes in ocular aberrations after instillation of artificial tears in dry-eye patients. J Cataract Refract Surg 2004;30:1649–1652.
12.
Ridder WH 3rd, Tomlinson A, Paugh J: Effect of artificial tears on visual performance in subjects with dry eye. Optom Vis Sci 2005;82:835–842.
13.
Ridder WH 3rd, Lamotte JO, Ngo L, Fermin J: Short-term effects of artificial tears on visual performance in normal subjects. Optom Vis Sci 2005;82:370–377.
14.
Taylor HR. Trachoma. Int Ophthalmol 1990;14:201–204.
15.
Guzey M, Ozardali I, Basar E, Aslan G, Satici A, Karadede S: A Survey of Trachoma: The histopathology and the mechanism of progressive cicatrisation of eyelid tissues. Ophthalmologica 2000;214:277–284.
16.
Guzey M, Satici A, Karadede S: Corneal thickness in trachomatous dry eye. Eur J Ophthalmol 2002;12:18–23.
17.
Birt CM, Shin DH, Samudrala V, Hughes BA, Kim C, Lee D: Analysis of reliability indices from Humphrey visual field tests in an urban glaucoma population. Ophthalmology 1997;104:1126–1230.
18.
Gonzalez de la Rosa M, Pareja A: Influence of the ‘fatigue effect’ on the mean deviation measurement in perimetry. Eur J Ophthalmol 1997;7:29–34.
19.
Heijl A, Asman P: Pitfalls of automated perimetry in glaucoma diagnosis. Curr Opin Ophthalmol 1995;6:46–51.
20.
Glass E, Schaumberger M, Lachenmayr BJ: Simulations for FASTPAC and the standard 4–2 dB full-threshold strategy of the Humphrey Field Analyzer. Invest Ophthalmol Vis Sci 1995;36:1847–1854.
21.
O’Brien C, Poinoosawmy D, Wu J, Hitchings R: Evaluation of the Humphrey FASTPAC threshold program in glaucoma. Br J Ophthalmol 1994;78:516–519.
22.
Thylefors B, Dawson CR, Jones BR, West SK, Taylor HR: A simple system for the assessment of trachoma and its complications. Bull World Health Organ 1987;65:447–483.
23.
The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 2007;5:75–92.
24.
Latkany R: Dry eyes: etiology and management. Curr Opin Ophthalmol 2008;19:287–291.
25.
Rolando M, Refojo MG, Kenyon KR: Increased tear evaporation in eyes with keratoconjunctivitis sicca. Arch Ophthalmol 1983;101:557–558.
26.
Bron AJ, Tiffany JM: The contribution of meibomian gland disease to dry eye. Ocul Surf 2004;2:149–165.
27.
Hong S, Lee CS, Seo KY, Seong GJ, Hong YJ: Effects of topical antiglaucoma application on conjunctival impression cytology specimens. Am J Ophthalmol 2006;142:185–186.
28.
Cvenkel B, Ihan A: Ocular surface changes induced by topical antiglaucoma monotherapy. Ophthalmologica 2002;216:175–179.
29.
Ishibashi T, Yokoi N, Kinoshita S: Comparison of the short-term effects on the human corneal surface of topical timolol maleate with and without benzalkonium chloride. J Glaucoma 2003;12:486–490.
30.
Leung EW, Medeiros FA, Weinreb RN: Prevalence of ocular surface disease in glaucoma patients. J Glaucoma 2008;17:350–355.
31.
Montés-Micó R, Alió JL, Charman WN: Dynamic changes in the tear film in dry eyes. Invest Ophthalmol Vis Sci 2005;46:1615–1619.
32.
Latkany R, Lock BG, Speaker M: Tear film normalization test: a new diagnostic test for dry eyes. Cornea 2006;25:1153–1157.
33.
Montés-Micó R, Cáliz A, Alió JL: Wavefront analysis of higher-order aberrations in dry eye patients. J Refract Surg. 2004;20:243–247.
34.
Christensen MT, Cohen S, Rinehart J, Akers F, Pemberton B, Bloomenstein M, Lesher M, Kaplan D, Meadows D, Meuse P, Hearn C, Stein JM: Clinical evaluation of an HP-guar gellable lubricant eye drop for the relief of dryness of the eye. Curr Eye Res 2004;28:55–62.
35.
Ubels JL, Clousing DP, Van Haitsma TA, Hong BS, Stauffer P, Asgharian B, Meadows D: Pre-clinical investigation of the efficacy of an artificial tear solution containing hydroxypropyl-guar as a gelling agent. Curr Eye Res 2004;28:437–444.
36.
Korb DR, Scaffidi RC, Greiner JV, Kenyon KR, Herman JP, Blackie CA, Glonek T, Case CL, Finnemore VM, Douglass T: The effect of two novel lubricant eye drops on tear film lipid layer thickness in subjects with dry eye symptoms. Optom Vis Sci 2005;82:594–601.
37.
López Bernal D, Ubels JL: Artificial tear composition and promotion of recovery of the damaged corneal epithelium. Cornea 1993;12:115–120.
38.
López Bernal D, Ubels JL: Quantitative evaluation of the corneal epithelial barrier: effect of artificial tears and preservatives. Curr Eye Res 1991;10:645–656.
39.
Lu C, Kostanski L, Ketelson H, Meadows D, Pelton R: Hydroxypropyl guar-borate interactions with tear film mucin and lysozyme. Langmuir 2005;21:10032–10037.
40.
Petricek I, Berta A, Higazy MT, Németh J, Prost ME: Hydroxypropyl-guar gellable lubricant eye drops for dry eye treatment. Expert Opin Pharmacother 2008;9:1431–1436.
41.
Korb DR, Baron DF, Herman JP, Finnemore VM, Exford JM, Hermosa JL, Leahy CD, Glonek T, Greiner JV: Tear film lipid layer thickness as a function of blinking. Cornea 1994;13:354–359.
42.
Korb DR, Greiner JV, Glonek T: Tear film lipid layer formation: implications for contact lens wear. Optom Vis Sci 1996;73:189–192.
43.
Gifford P, Evans BJ, Morris J: A clinical evaluation of Systane. Cont Lens Anterior Eye 2006;29:31–40.
44.
Noecker RJ: Comparison of initial treatment response to two enhanced-viscosity artificial tears. Eye Contact Lens 2006;32:148–152.
45.
Argüeso P, Gipson IK: Epithelial mucins of the ocular surface: structure, biosynthesis and function. Exp Eye Res 2001;73:281–289.
46.
Ousler GW, Michaelson C, Christensen MT: An evaluation of tear film breakup time extension and ocular protection index scores among three marketed lubricant eye drops. Cornea 2007;26:949–952.
47.
Schaumberger M, Schäfer B, Lachenmayr BJ: Glaucomatous visual fields. FASTPAC versus full threshold strategy of the Humphrey Field Analyzer. Invest Ophthalmol Vis Sci 1995;36:1390–1397.
48.
Hudson C, Wild JM, O’Neill EC: Fatigue effects during a single session of automated static threshold perimetry. Invest Ophthalmol Vis Sci 1994;35:268–280.
49.
Rieger G: The importance of the precorneal tear film for the quality of optical imaging. Br J Ophthalmol 1992;76:157–158.
50.
Yenice O, Temel A, Orum O: The effect of artificial tear administration on visual field testing in patients with glaucoma and dry eye. Eye 2007;21:214–217.
51.
Heijl A, Bengtsson B: The effect of perimetric experience in patients with glaucoma. Arch Ophthalmol 1996;114:19–22.
52.
Werner EB, Krupin T, Adelson A, Feitl ME: Effect of patient experience on the results of automated perimetry in glaucoma suspect patients. Ophthalmology 1990;97:44–48.
53.
Olsson J, Asman P, Heijl A: A perimetric learner’s index. Acta Ophthalmol Scand 1997;75:665–668.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.